TITAN PHARMACEUTICALS INC — Proxy Solicitation & Information Statement 2020

Nov 9, 2020

DEFA14A 1 tm2035487-1_defa14a.htm DEFA14A

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A (Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant x

Filed by a party other than the Registrant ¨

Check the appropriate box:

¨ Preliminary proxy statement

¨ Confidential, For use of the Commission only (as permitted by Rule 14a-6(e)(2))

¨ Definitive proxy statement

x Definitive additional materials

¨ Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12

Titan Pharmaceuticals, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of filing fee (Check the appropriate box):

x No fee required.

¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)	Title of each class of securities to which transaction applies:
(2)	Aggregate number of securities to which transaction applies:
(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
(4)	Proposed maximum aggregate value of transaction:
(5)	Total fee paid:
¨	Fee paid previously with preliminary materials:
¨	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
(1)	Amount previously paid:
(2)	Form, Schedule or Registration Statement No.:
(3)	Filing Party:
(4)	Date Filed:

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

November 9, 2020

To Our Stockholders:

Please be advised that the meeting date of the special meeting of the stockholders of Titan Pharmaceuticals, Inc. (the “Special Meeting”) originally scheduled for 9:00 a.m. Pacific time on November 16, 2020 has been moved to 9:00 a.m. Pacific time on November 30, 2020. The change in the meeting date is to provide brokerage firms and banks sufficient time to exercise their discretion to vote your shares on the reverse stock split proposal being presented at the Special Meeting.

The record date for stockholders entitled to vote at the Special Meeting remains October 30, 2020.

If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, Alliance Advisors LLC, at the following toll free number:

866-619-4651

Field: Page; Sequence: 3; Options: Last

Field: /Page